Depletion of insulin receptor substrate 2 reverses oncogenic transformation induced by v-src

Acta Pharmacologica Sinica

Volumn 32, Issue 5, 2011, Pages 611-618

  Sun, Hong Zhi ^a   Xu, Lin ^a   Zhou, Bo ^a   Zang, Wei Jin ^a   Wu, Shu Fang ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

cellular transformation; cyclin D1 promoter; insulin receptor substrate 2 (IRS 2); nuclear translocation; rDNA promoter; RNA interference; v src

Indexed keywords

CYCLIN D1; INSULIN RECEPTOR SUBSTRATE 2; NUCLEOLIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE P60; PROTEIN P85; RIBOSOME DNA; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL FRACTIONATION; CELL PROLIFERATION; CELL TRANSFORMATION; CHROMATIN IMMUNOPRECIPITATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DEPLETION; ENZYME SUBUNIT; GENE SILENCING; MOUSE; NONHUMAN; PLASMID; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE;

3T3 CELLS; ANIMALS; BINDING SITES; CELL LINE, TUMOR; CELLS, CULTURED; DNA, RIBOSOMAL; FIBROBLASTS; GENE SILENCING; INSULIN RECEPTOR SUBSTRATE PROTEINS; MICE; ONCOGENE PROTEIN PP60(V-SRC); PHOSPHATIDYLINOSITOL 3-KINASES; PROMOTER REGIONS, GENETIC; RECEPTOR, IGF TYPE 1; RNA, SMALL INTERFERING;

EID: 79959719193     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.18     Document Type: Article

References (29)

1. Nagle JA, Ma ZF, Byrne MA, White MF, Shaw LM. Involvement of insulin receptor substrate 2 in mammary tumor metastasis. Mol Cell Biol 2004; 24: 9726-35. (Pubitemid 39458801)
2. Baserga R, Peruzzi F, Reiss K. The IGF-I receptor in cancer biology. Int J Cancer 2003; 107: 873-7.
3. Baserga R. The insulin-like growth factor-1 receptor as a target for cancer therapy. Expert Opin Ther Targets 2005; 9: 753-68. (Pubitemid 41131677)
4. Sun H, Tu X, Prisco M, Wu A, Casiburi I, Baserga R. Insulin-like growth factor I receptor signaling and nuclear translocation of insulin receptor substrates 1 and 2. Mol Endocrinol 2003; 17: 472-86. (Pubitemid 36315640)
5. Dearth RK, Cui XJ, Kim HJ, Hadsell DL, Lee AV. Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle 2007; 6: 705-13. (Pubitemid 46535683)
6. Sun H, Baserga R. Deletion of the pleckstrin and phosphotyrosine binding domains of insulin receptor substrate-2 does not impair its ability to regulate cell proliferation in myeloid cells. Endocrinology 2004; 145: 5332-43. (Pubitemid 39551155)
7. Dalmizrak O, Wu A, Chen J, Sun H, Utama FE, Zambelli D, et al. Insulin receptor substrate-1 regulates the transformed phenotype of bt-20 human mammary cancer cells. Cancer Res 2007; 67: 2124-30. (Pubitemid 46424231)
8. Reiss K, Wang JY, Romano G, Tu X, Peruzzi F, Baserga R. Mechanism of regulation of cell adhesion and motility by insulin receptor substrate- 1 in prostate cancer cells. Oncogene 2001; 20: 490-500. (Pubitemid 32158229)
9. Sun H, Tu X, Baserga R. A mechanism for cell size regulation by the insulin and IGF-1 receptors. Cancer Res 2006; 66: 11106-9. (Pubitemid 46009934)
10. Drakas R, Tu X, Baserga R. Control of cell size through phosphorylation of upstream binding factor1 by nuclear phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A 2004; 101: 9272-6. (Pubitemid 38812865)
11. Baserga R. Customizing the targeting of IGF-1 receptor. Future Oncol 2009; 5: 43-50.
12. Voit R, Grummt I. Phosphorylation of UBF at serine 388 is required for interaction with RNA polymerase I and activation of rDNA transcription. Proc Natl Acad Sci U S A 2001; 98: 13631-6. (Pubitemid 33115949)
13. Comai L, Song Y, Tan C, Bui T. Inhibition of RNA polymerase I transcription in differentiated myeloid leukemia cells by inactivation of selectivity factor-1. Cell Growth Diff 2000; 11: 63-70. (Pubitemid 30078667)
14. Sun H, Baserga R. The role of insulin receptor substrate-1 in transformation by v-src. J Cell Physiol 2008; 215: 725-32. (Pubitemid 351632694)
15. White MF. The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol Cell Biochem 1998; 182: 3-11. (Pubitemid 28181643)
16. Klippel A, Escobedo MA, Wachowicz MS, Apell G, Brown TW, Giedlin MA, et al. Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation. Mol Cell Biol 1998; 18: 5699-711. (Pubitemid 28450521)
17. Byron SA, Horwitz KB, Richer JK, Lange CA, Zhang X, Byron SA, et al. Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells. Br J Cancer 2006; 95: 120-8.
18. DeAngelis T, Chen J, Wu A, Prisco M, Baserga R. Transformation by the Simian Virus 40 T antigen is regulated by IGF-1 receptor and IRS-1 signaling. Oncogene 2006; 25: 32-42. (Pubitemid 43050001)
19. Del Rincon SV, Guo Q, Morelli C, Shiu HY, Surmacz E, Miller WH. Retinoic acid mediates degradation of IRS-1 by the ubiquitin-proteasome pathway, via a PKC-dependent mechanism. Oncogene 2004; 23: 9269-79. (Pubitemid 40069697)
20. Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, et al. Multiple signaling pathways of the IGF-I receptor in protection from apoptosis. Mol Cell Biol 1999; 19: 7203-15. (Pubitemid 29441900)
21. Yenush L, Fernandez R, Myers MG Jr, Grammer TC, Sun XJ, Blenis J, et al. The Drosophila insulin receptor activates multiple signaling pathways but requires insulin receptor substrate proteins for DNA synthesis. Mol Cell Biol 1996; 16: 2509-17. (Pubitemid 26123772)
22. Comai L, Song Y, Tan C, Bui T. Inhibition of RNA polymerase I transcription in differentiated myeloid leukemia cells by inactivation of selectivity factor-1. Cell Growth Diff 2000; 11: 63-70. (Pubitemid 30078667)
23. Baserga R. Customizing the targeting of IGF-1 receptor. Future Oncol 2009; 5: 43-50.
24. Sawka-Verhelle D, Tartare-Deckert S, White MF, van Obberghen E. Insulin receptor substrate-2 binds to the insulin receptor through its phosphotyrosine-binding domain and through a newly identified domain comprising amino acids 591-786. J Biol Chem 1996; 271: 5980-3.
25. Drakas R, Tu X, Baserga R. Control of cell size through phosphorylation of upstream binding factor1 by nuclear phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A 2004; 101: 9272-6. (Pubitemid 38812865)
26. Huang C, Thirone ACP, Huang X, Klip A. Differential contribution of insulin receptor substrate-1 versus 2 to insulin signaling and glucose uptake in L6 myotubes. J Biol Chem 2005; 280: 19426-35. (Pubitemid 41379651)
27. Stefanovsky VY, Pelletier G, Hannan R, Gagnon-Kugler T, Rothblum LI, Moss T. An immediate response of ribosomal transcription to growth factor stimulation in mammals is mediated by ERK phosphorylation of UBF. Mol Cell 2001; 8: 1063-73. (Pubitemid 34031808)
28. Klippel A, Escobedo MA, Wachowicz MS, Apell G, Brown TW, Giedlin MA, et al. Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation. Mol Cell Biol 1998; 18: 5699-711. (Pubitemid 28450521)
29. Bader AG, Vogt PK. An essential role for protein synthesis in oncogenic cellular transformation. Oncogene 2004; 23: 3145-50. (Pubitemid 38638826)